Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

Affiliations

¹ Department of Internal Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
² Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

Samet Yaman et al. Future Oncol. 2019 Mar.

. 2019 Mar;15(9):925-927.

doi: 10.2217/fon-2018-0503. Epub 2019 Mar 11.

¹ Department of Internal Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
² Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.

No abstract available

Keywords: immunotherapy; renal cell carcinoma; tyrosine kinase inhibitors.

Similar articles

In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Jul 18;58(1499):e97. Med Lett Drugs Ther. 2016. PMID: 27403787 No abstract available.
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G, Generali D. Roviello G, et al. Eur Urol. 2017 Dec;72(6):1027-1028. doi: 10.1016/j.eururo.2017.07.019. Epub 2017 Jul 29. Eur Urol. 2017. PMID: 28760645 No abstract available.
Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF, Canda AE, Dizdar O, Altinova S, Akbulut Z, Balbay MD. Ozcan MF, et al. Eur Urol. 2011 Jun;59(6):e34. doi: 10.1016/j.eururo.2011.02.038. Epub 2011 Mar 12. Eur Urol. 2011. PMID: 21398023 No abstract available.
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Umeyama Y, Shibasaki Y, Akaza H. Umeyama Y, et al. Future Oncol. 2017 Sep;13(21):1839-1852. doi: 10.2217/fon-2017-0104. Epub 2017 Jul 14. Future Oncol. 2017. PMID: 28707479 Review.
Temsirolimus in the treatment of advanced renal cell carcinoma.
Gore ME. Gore ME. Ann Oncol. 2007 Jul;18 Suppl 9:ix87-8. doi: 10.1093/annonc/mdm299. Ann Oncol. 2007. PMID: 17631601 Review. No abstract available.